why is crsp stock down

Out of 9 analysts, 4 (44.44%) are recommending CRSP as a Strong Buy, 1 (11.11%) are recommending CRSP as a...

Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeutics. The biotech firm Vertex Pharmaceuticals is paying $900 million...